Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab versus continued daratumumab + lenalidomide + dexamethasone in newly diagnosed transplant-ineligible multiple myeloma
2024-519827-16-00Phase 3Authorised
- Sponsor
- European Myeloma Network
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of linvoseltamab, daratumumab, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by European Myeloma Network. Primary endpoints: MRD-negative complete response at 10^-5 and Progression-free survival. Planned start Sep 2025; status: authorised.
02
Drugs
linvoseltamabdaratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-519827-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519827-16-00.